The Emerging Picture of Anemia in Chronic Kidney DiseaseA Foundation for Managed Care
Mehdi U, Toto RD. Diabetes Care. 2009;32(7):1320-1326.
Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature.
van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. J Med Econ. 2010;13(2):241-256.
Stauffer ME, Fan T. PLoS One. 2014;9(1):e84943.
Geddes CC. Nephrol Dial Transplant. 2019;34(6):921-922.
Intravenous iron in patients undergoing maintenance hemodialysis [published correction appears in N Engl J Med. 2019;380(5):502].
Macdougall IC, White C, Anker SD, et al; for the PIVOTAL Investigators and Committees. N Engl J Med. 2019;380(5):447-458.
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC, Bock AH, Carrera F, et al. Nephrol Dial Transplant. 2014;29(11):2075-2084.
Chen N, Hao C, Peng X, et al. N Engl J Med. 2019;381(11):1001-1010.
Chen N, Hao C, Liu B-C. N Engl J Med. 2019;381(11):1011-1022.
OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent CKD and anemia.
Fishbane S, et al. American Society of Nephrology (ASN) Kidney Week; November 5-10, 2019; Washington, DC. Abstract TH-OR023.
ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients.
Fishbane S, et al. ASN Kidney Week; November 5-10, 2019; Washington, DC. Abstract TH-OR022.
HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients.
Provenzano R, et al. ASN Kidney Week; November 5-10, 2019; Washington, DC. Abstract TH-OR121.
Pooled efficacy and CV analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis.
Provenzano R, et al. ASN Kidney Week; November 5-10, 2019; Washington, DC. Abstract FR-OR131.
A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
Bailey CK, Caltabiano S, Cobitz AR, Huang C, Mahar KM, Patel VV. BMC Nephrol. 2019;20(1):372.
Schödel J, Ratcliffe PJ. Nat Rev Nephrol. 2019;15(10):641-659.
Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. BMJ Open. 2019;9(6):e026704.
Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease.
Akizawa T, Macdougall IC, Berns JS, et al. Nephron. 2019;143(4):243-254.
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease.
Sakashita M, Tanaka T, Nangaku M. Contrib Nephrol. 2019;198:112-123.
McMahon GM, Singh AK. Curr Opin Nephrol Hypertens. 2019;28(6):600-606.
Pfeffer MA, Burdmann EA, Chen C-Y, et al; for the TREAT Investigators. N Engl J Med. 2009;361(21):2019-2032.
McCullough PA, Barnhart HX, Inrig JK, et al. Am J Nephrol. 2013;37(6):549-558.
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Inrig JK, Barnhart HX, Reddan D, et al. Am J Kidney Dis. 2012;60(3):390-401.
Hasegawa T, Koiwa F, Akizawa T. Semin Dial. 2018;31(6):599-606.
Locatelli F, Del Vecchio L, Pozzoni P. J Am Soc Nephrol. 2006;17(12 suppl 3):S262-S266.
The HIF System in Anemia of Chronic Kidney Disease
Presented by Bruce S. Spinowitz, MD
A Foundation for Managed Care
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors